|
TOP |
1 |
1.
Digital design and manufacturing of the Lingualcare bracket system. |
2 | 2.
Circulating levels of prolactin in breast cancer patients. Mujagić Z., Mujagić H., Prnjavorac B. Med Arh200559:1(33-35) MEDLINE ![]() |
3 | 3.
Importance of serum prolactin determination in metastatic breast
cancer patients Mujagić Z., Mujagić H. Croat. Med. J.200445:2(176-180) EMBASE ![]() |
4 | 4.
Inhalation of gasoline and damage to health in workers at gas
stations Pranjić N., Mujagić H., Pavlović S. Med Arh200357:1(17-20) MEDLINE ![]() |
5 | 5.
Alcohol in alcoholic liver disease is a causative factor for
development of allergic skin manifestations. Mujagić H., Prnjavorac B., Mujagic Z., Festa G. Med Arh200357:5-6(273-278) MEDLINE ![]() |
6 | 6.
Mechanisms of action and potential therapeutic uses of thalidomide Mujagić H., Chabner B.A., Mujagić Z. Croat. Med. J.200243:3(274-285) EMBASE ![]() |
7 | 7.
Precarcinoma and early carcinomatous lesions in the uterine cervix
and the use of oral contraceptives Ljuca D., Fatusić Z., Mujagić H., Ljuca F., Alispahić N. Med Arh200054:2(71-73) MEDLINE ![]() |
8 | 8.
Quality of medical records as a basis for DRG classification in the
health care system in Bosnia-Herzegovina Sabanović Z., Mujagić H., Bazardzanović M. Med Arh199953:3 Suppl 3(61-64) MEDLINE ![]() |
9 | 9.
Detection of pleiotropic drug resistance by the rapid
immunofluorescence assay of drug effects on the cell skeleton Mujagic H., Mujagic Z. ONCOLOGY199148:3(202-209) EMBASE ![]() |
10 | 10.
The levels and relations of prostaglandins in pregnant and
non-pregnant tumor-bearing mice Mujagic H., Krnjajic N., Jevric A. J. CANCER RES. CLIN. ONCOL.1989115:4(383-387) EMBASE ![]() |
11 | 11.
Comparison of PGE1 and PGE2 levels in pregnant syngeneic BALB/C mice
with transplanted fibrosarcoma. Krnjaić N., Jevrić A., Krnjaić Z., Filipović I., Mujagić H. Prog Clin Biol Res1987242:-(119-122) MEDLINE ![]() |
12 | 12.
Quantitative changes in surface immunoglobulin expression in
WEHI-231 lymphoma cells in relation to their proliferative rate Mujagic H., Shackney S.E., Smith C.E., Chen S.S. ONCOLOGY198643:4(237-242) EMBASE ![]() |
13 | 13.
Detection of pleiotropic drug resistance (PDR) by immunofluorescent
assay of drug effects on cytoskeleton Mujagic H., Hamel E., Curt G., Chabner B.A. PROC. AM. ASSOC. CANCER RES.1985VOL. 26:-(No. 1331) EMBASE ![]() |
14 | 14.
Schedule dependence of vincristine lethality in Sarcoma 180 cells
following partial synchronization with hydroxyurea Mujagic H., Conger B.M., Smith C.A. CANCER RES.198343:8(3598-3603) EMBASE ![]() |
15 | 15.
Effects of vincristine on cell survival, cell cycle progression, and
mitotic accumulation in asynchronously growing sarcoma 180 cells Mujagic H., Chen S.S., Geist R. CANCER RES.198343:8(3591-3597) EMBASE ![]() |
16 | 16.
Studies on the lethal and sublethal effects of vincristine (VCR) in
sarcoma 180 in vitro Conger B., Occhipinti S.J., Mujagic H. CELL TISSUE KINET.198215:6(674) EMBASE ![]() |
17 | 17.
The significance of tuberculin immunity testing in cancer patients Mujagic H., Deskovic M., Malenica B. CELL. MOL. BIOL.198026:2(111-121) EMBASE ![]() |
18 | 18.
BCG immunotherapy in previously treated malignant melanoma patients Mujagic H., Kolaric K., Malenica B., Nola P. BIOMEDICINE197930:2(95-102) EMBASE ![]() |
19 | 19.
Possibilities of immunotherapy of malignant tumors in men Mujagic H. MED. ARH.197832:1(43-49) EMBASE ![]() |
20 | 20.
Possibilities of immunotherapy in malignant tumors in man Mujagić H. Med Arh197832:1(43-49) MEDLINE ![]() |
21 | 21.
In vitro detection of cellular immunity to melanoma antigens in man
by the monocyte spreading inhibition test Mazuran R., Mujagic H., Malenica B., Silobrcic V. INT. J. CANCER197617:1(14-20) EMBASE ![]() |
22 | 22.
The effect of splenectomy on fibrosarcoma "metastases" in lungs of
mice. Milas L., Mujagic H. Int J Cancer197311:1(186-190) MEDLINE ![]() |
23 | 23.
Experimental lung metastases as a test in tumour immunology Silobrcic V., Milas L., Mujagic H. IARC SCI. PUBL.1973vol.7:-(411-417) EMBASE ![]() |
24 | 24.
Protection by Corynebacterium parvum against tumour cells injected
intravenously. .Milas L., Mujagić H. Rev Eur Etud Clin Biol197217:5(498-500) MEDLINE ![]() |
![]() |